BriaCell Therapeutics (BCTX) vs Telomir Pharmaceuticals (TELO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BriaCell Therapeutics (BCTX) has outperformed Telomir Pharmaceuticals (TELO) over the past year, losing 61.7% versus a loss of 71.6%. Telomir Pharmaceuticals is the larger company by market cap ($26.8 million vs $26.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCTX | TELO |
|---|---|---|
| Share price | $3.06 | $0.364 |
| Market cap | $26.72M | $26.82M |
| 1-day change | -3.32% | -17.24% |
| YTD return | -56.96% | -72.63% |
| 1-year return | -61.75% | -71.56% |
| 5-year return | -97.00% | — |
| EPS (TTM) | $-6.97 | $-0.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-34.90M | $-10.41M |
| 52-week high | $13.09 | $1.58 |
| 52-week low | $2.60 | $0.353 |
| Distance from 52-week high | -76.62% | -76.96% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +998.90% |
| Average volume | 250.81K | 126.14K |
| Shares outstanding | 8.73M | 73.68M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BriaCell Therapeutics
BCTX stock →BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations
About Telomir Pharmaceuticals
TELO stock →Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria.
Health Care · Biotechnology: Pharmaceutical Preparations
BCTX vs TELO FAQ
Which is bigger, BriaCell Therapeutics or Telomir Pharmaceuticals?
Telomir Pharmaceuticals (TELO) is larger, with a market capitalization of $26.82M compared with $26.72M for BriaCell Therapeutics (BCTX).
Which stock has performed better over the past year, BCTX or TELO?
BCTX returned -61.75% over the past 12 months, compared with -71.56% for TELO (price return, excluding dividends). Past performance does not predict future results.
Are BriaCell Therapeutics and Telomir Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.